• 下载App


  • 在线客服

成功领取价值超 5000港元/年的高级行情
前往体验 >>

CB Scientific, Inc. Concludes Its Special Meeting of Stockholders
CB Science,Inc.结束股东特别大会

Accesswire ·  {{timeTz}}

Commanding shareholder approval better positions management to attain enterprise business objectives going forward


ESCONDIDO, CA / ACCESSWIRE / January 18, 2022 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced today that the company successfully concluded its Special Meeting of Stockholders ("Special Meeting") on Friday, January 14, 2022, as planned. Votes representing approximately 73% of the total eligible shares were counted, and each of the 5 proposals on the agenda passed by a wide margin. Efforts regarding certain matters including reincorporation of the Company from Oregon to Nevada, pursuant to a merger of the Company with and into a newly formed Nevada corporation and resulting in a change in name of the Company to Cardiac Biotech Solutions, Inc., are expected to commence immediately.

加利福尼亚州埃斯孔迪多/ACCESSWIRE/2022年1月18日/亚洲网加利福尼亚州圣何塞1月14日电CB Science,Inc.(场外粉色交易代码:CBSC)(以下简称“CBSC”或“公司”)今天宣布,公司按计划于2022年1月14日(星期五)圆满结束了股东特别大会(“特别会议”)。大约占合格股份总数73%的选票被清点完毕,议程上的5项提案每一项都以较大优势获得通过。有关某些事项的工作,包括根据公司与新成立的内华达州公司合并,并将公司名称改为心脏生物技术解决方案公司,将公司从俄勒冈州重新注册到内华达州,预计将立即开始。

"We were extremely pleased that an overwhelming majority of our shareholders exhibited ample trust and confidence in management's recommendations to vote accordingly," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "Each of these actions were carefully contemplated and deliberately designed to provide the Company with critical tools we require to pursue planned business objectives. Now armed with a clear shareholder mandate, we are ready to move forward without delay."

CB Science,Inc.首席执行官查尔斯·马丁说:“我们感到非常高兴的是,我们的绝大多数股东对管理层提出的相应投票建议表现出了充分的信任和信心。”“每一项行动都经过深思熟虑和刻意设计,目的是为公司提供我们实现计划中的业务目标所需的关键工具。现在有了明确的股东授权,我们已经准备好毫不拖延地向前推进。”

"Looking to the future, the Company is now even better positioned for a potential listing on the Nasdaq exchange at the right time," said Paul Danner, Chairman of CB Scientific, Inc. "With the stockholder-approved increase in common shares, coupled with management's ability to initiate a reverse stock split should it be necessary, the Company can prudently manage its share price based on current market requirements. To be clear, a reverse stock split will be effected only if it is necessary to satisfy the initial or continued listing standards or requirements of The Nasdaq Capital Market or another national securities exchange."

CB Science,Inc.董事长保罗·丹纳说:“展望未来,本公司现在为在正确的时间在纳斯达克交易所上市做好了更好的准备。”“股东批准增持普通股,再加上管理层有能力在必要时发起反向股票分拆,本公司可以根据当前市场要求审慎管理其股价.需要明确的是,只有在有必要满足纳斯达克资本市场或另一家全国性证券交易所的初始或继续上市标准或要求的情况下,才会实施反向股票分拆.”

As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

随着更多新情况的出现,CB Science,Inc.计划通过新闻稿和监管文件及时发布公告,使其股东、行业参与者和公开市场随时了解情况。

About CB Scientific, Inc.
CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

关于CB Science,Inc.
CB Science,Inc.通过其国内和国际子公司,在非侵入性非侵入性心脏监测领域提供创新的产品和服务。我们的FDA和CE批准的EKG设备、基于云的交互式采集软件以及适用于iOS和Android平台的智能手机应用程序为有心律异常风险的患者提供了更好的遵从性,并为医生提供了更准确的信息。

Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

电子邮件:General Queries:info@cbSciences ficinc.com
投资者咨询:Robert Hesse-dorchco.bh@gmail.com

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.


SOURCE: CB Scientific, Inc.

资料来源:CB Science,Inc.

View source version on accesswire.com: